Petosemtamab Antibody

SKU: orb1980554

Description

Petosemtamab (MCLA-158) is a potent bispecific antibody targeting EGFR and LGR5, disrupting oncogenic signaling and inducing receptor degradation. It is utilized in preclinical research for solid tumors, including head and neck squamous cell carcinoma and colorectal cancer, with studies demonstrating activity in both in vitro and in vivo models.

Research Area

Cardiovascular Research, Signal Transduction

Images & Validation

−

Key Properties

−

CAS Number	2213450-26-9
MW	145.97 kDa
Purity	> 95%
Target	EGFR

Bioactivity

−

Target IC50	EGFR:0.22 nM (Kd)\|LGR5:0.85 nM (Kd)
In Vivo	Treatment with MCLA-158(Petosemtamab) (25 mg/kg/week, intravenous injection, for 6 weeks) leads to tumor regression in esophageal squamous cell carcinoma, gastric adenocarcinoma, and head and neck PDX models. Read more...
In Vitro	Treatment with MCLA-158(Petosemtamab) (1 µg/mL; 24 or 72 hours) induces the degradation of EGFR in EGFR+/LGR5+ colorectal cancer organoids.

Storage & Handling

−

Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

Petosemtamab, MCLA 158, MCLA158, MCLA-158, EGFR

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Quick Database Links

Gene Symbol

EGFR

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols